Lymphodepletion (Ld), Tumor-Infiltrating Lymphocytes (Til) And High (Hd-Il2) Versus Low-Dose (Ld-Il2) Il-2 Followed By Pembrolizumab (Pembro) In Patients (Pts) With Metastatic Melanoma (Mm).